Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q4QV
|
|||
| Former ID |
DIB005926
|
|||
| Drug Name |
TPIV100
|
|||
| Indication | HER2-positive breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Company |
Tapimmune
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04197687) TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.